公开(公告)号：US20190015402A1

公开(公告)日：2019-01-17

申请号：US16042447

申请日：2018-07-23

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K31/454 ,  A61K31/4418 ,  C07D401/14 ,  A61K45/06 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K31/435 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4178 ,  C07F7/02 ,  C07D491/113 ,  C07D453/00 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/14 ,  A61K31/4439

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US10039754B2

公开(公告)日：2018-08-07

申请号：US15431069

申请日：2017-02-13

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  A61K31/454 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/4355 ,  A61K31/4178

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US10028937B2

公开(公告)日：2018-07-24

申请号：US15434789

申请日：2017-02-16

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean-Christophe C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  C07K16/00 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/4439 ,  A61K31/422 ,  A61K31/4418 ,  A61K31/4545 ,  A61K31/695 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/438 ,  A61K31/435

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20150218194A1

公开(公告)日：2015-08-06

申请号：US14683910

申请日：2015-04-10

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean C. Califano ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: C07F9/6558 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D207/09 ,  C07D491/113 ,  C07D413/14 ,  C07D471/04 ,  C07C201/06 ,  C07D207/08 ,  C07D207/16 ,  C07D417/14

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：US09006387B2

公开(公告)日：2015-04-14

申请号：US14180886

申请日：2014-02-14

Applicant: AbbVie, Inc.

Inventor： Rolf Wagner ,  John K. Pratt ,  Dachun Liu ,  Michael D. Tufano ,  David A. DeGoey ,  Warren M. Kati ,  Charles W. Hutchins ,  Pamela L. Donner ,  John T. Randolph ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  Mark A. Matulenko ,  Ryan G. Keddy ,  Tammie K. Jinkerson ,  Todd W. Rockway ,  Clarence J. Maring ,  Douglas K. Hutchinson ,  Charles A. Flentge ,  David A. Betebenner ,  Kathy Sarris ,  Kevin R. Woller ,  Seble H. Wagaw ,  Jean C. Califano ,  Wenke Li ,  Daniel D. Caspi ,  Mary E. Bellizzi ,  Yi Gao ,  Allan C. Krueger

IPC: C07K16/00 ,  A61K38/00 ,  C07K5/06 ,  C07D401/14 ,  C07D403/14 ,  C07D417/14 ,  C07C33/26 ,  C07C205/19

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20150087618A1

公开(公告)日：2015-03-26

申请号：US14558318

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: C07F7/02 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D413/14

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US09586978B2

公开(公告)日：2017-03-07

申请号：US14558318

申请日：2014-12-02

Applicant: AbbVie Inc.

Inventor： Mary E. Bellizzi ,  David A. Betebenner ,  Jean C. Califano ,  William A. Carroll ,  Daniel D. Caspi ,  David A. DeGoey ,  Pamela L. Donner ,  Charles A. Flentge ,  Yi Gao ,  Charles W. Hutchins ,  Douglas K. Hutchinson ,  Tammie K. Jinkerson ,  Warren M. Kati ,  Ryan G. Keddy ,  Allan C. Krueger ,  Wenke Li ,  Dachun Liu ,  Clarence J. Maring ,  Mark A. Matulenko ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  John K. Pratt ,  John T. Randolph ,  Todd W. Rockway ,  Kathy Sarris ,  Michael D. Tufano ,  Seble H. Wagaw ,  Rolf Wagner ,  Kevin R. Woller

IPC: A61K38/00 ,  C07K16/00 ,  C07F7/02 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：US20140315792A1

公开(公告)日：2014-10-23

申请号：US14180886

申请日：2014-02-14

Applicant: AbbVie, Inc.

Inventor： Rolf Wagner ,  John K. Pratt ,  Dachun Liu ,  Michael D. Tufano ,  David A. DeGoey ,  Warren M. Kati ,  Charles W. Hutchins ,  Pamela L. Dooner ,  John T. Randolph ,  Christopher E. Motter ,  Lissa T. Nelson ,  Sachin V. Patel ,  Mark A. Matulenko ,  Ryan G. Keddy ,  Tammie K. Jinkerson ,  Todd W. Rockway ,  Clarence J. Maring ,  Douglas K. Hutchinson ,  Charles A. Flentge ,  David A. Betebenner ,  Kathy Sarris ,  Kevin R. Woller ,  Seble H. Wagaw ,  Jean C. Califano ,  Wenke Li ,  Daniel D. Caspi ,  Mary E. Bellizzi ,  Yi Gao ,  Allan C. Krueger

IPC: C07K5/06 ,  C07D417/14 ,  C07C33/26 ,  C07D403/14 ,  C07C205/19

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US08669255B2

公开(公告)日：2014-03-11

申请号：US13627541

申请日：2012-09-26

Applicant: AbbVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: A61K31/495

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Z 1，Z 2，Z 3，Z 4，R 1，R 2和R 3如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道抑制剂。

公开(公告)号：US08648074B2

公开(公告)日：2014-02-11

申请号：US13627536

申请日：2012-09-26

Applicant: AbbVie Inc.

Inventor： Tao Li ,  Sachin V. Patel ,  Richard J. Perner ,  John T. Randolph ,  Michael R. Schrimpf ,  Kevin R. Woller ,  Zhiren Xia ,  Qingwei Zhang

IPC: A61K31/495

CPC classification number: C07D487/04

Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z′, Z″, L2, G2, R1, and R2 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.

Abstract translation: 本申请涉及：（a）式（I）的化合物及其盐，其中Z'，Z“，L2，G2，R1和R2如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道阻滞剂。